More cancer drugs to become cheaper
Print Edition
China will make more cancer drugs affordable, as a new round of negotiations between the state medical insurance administration and pharmaceutical companies to add such drugs to the medical insurance list is scheduled to finish by the end of September.
The administration said it has selected a range of drugs to be added and is confirming the producers鈥 willingness to negotiate further.
All these drugs are of great clinical value and will bring huge benefits to patients with cancers or tumors, including colorectal cancer, renal cell carcinoma, lymphoma, and chronic myelogenous leukemia, said the administration.
China has exempted import tariffs from all common drugs, including cancer drugs, cancer alkaloid-based drugs, and imported traditional Chinese medicine since May 1.
Based on the new policy, 12 pharmaceutical companies have recalculated the prices of their products and will submit applications for price adjustments as per the administration鈥檚 requirement.
Talks launched in 2017 led to the lowering of prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib. They were also added to the medical insurance reimbursement list.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
